Comparison of salmefamol and salbutamol in patients with chronic airways obstruction.
1 Inhaled salmefamol, in doses of 100 mug and 200 mug has been compared with inhaled salbutamol, in a dose of 200 mug, and with placebo in patients with airways obstruction. 2 Both salmefamol and salbutamol are potent bronchodilators with a signficantly superior action over placebo at all times up to 8 h after treatment. 3 The mean peak percentage increases in FEV produced by the three active preparations were similar. The decline from peak values was significantly slower with salmefamol than with salbutamol. Neither drug produced tachycardia.
D000293:Adolescent; D000328:Adult; D000402:Airway Obstruction / Q000188:drug therapy*; D000420:Albuterol / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos
D004983:Ethanolamines; D010919:Placebos; D000420:Albuterol